FABP4 likely represents an important pathophysiological mediator of metabolic aberrations exerting a dramatic impact on obesity, insulin resistance, type 2 diabetes, fatty liver disease and atherosclerosis, all of which are conditions associated with the endocannabinoid system. Here, FABP4 is linked to type 2 diabetes mellitus.